Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy

BACKGROUND: Genetically engineered T cells are powerful anti-cancer treatments but are limited by safety and specificity issues. We herein describe a MHC-unrestricted modular platform combining autologous T cells, transduced with a targetable synthetic agonistic receptor (SAR), with bispecific antib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Karches, Clara H., Benmebarek, Mohamed-Reda, Schmidbauer, Moritz L., Kurzay, Mathias, Klaus, Richard, Geiger, Martina, Rataj, Felicitas, Cadilha, Bruno L., Lesch, Stefanie, Heise, Constanze, Murr, Ramona, Berg, Johannes vom, Jastroch, Martin, Lamp, Daniel, Ding, Jian, Duewell, Peter, Niederfellner, Gerhard, Sustmann, Claudio, Endres, Stefan, Klein, Christian, Kobold, Sebastian
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611266/
https://ncbi.nlm.nih.gov/pubmed/31285373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3927
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados